Company intelligence / Profile preview

Moligo Technologies

Solna, Sweden

Ownership: Private
Development stage: Other

Overview

Moligo Technologies develops ultrapure, long, and highly complex single-stranded DNA (ssDNA) sequences at industrial scale, primarily for applications in gene editing, gene therapy, diagnostics, and nanotechnology. Their patented enzymatic technology enables production of error-free DNA strands over 10,000 bases in length, supporting both viral and non-viral therapeutic approaches. Pre-clinical collaborations (e.g., with Nationwide Children’s Hospital for cystic fibrosis and Cellectis for hematopoietic stem cell gene editing) are ongoing, with the aim of advancing to clinical trials in the near future.

Therapeutic areas: OtherRare Diseases
Modalities: Single-stranded DNA oligonucleotideGene therapyCRISPR-based therapy
Industry: Biotech

Partnerships

GSKNationwide Children’s HospitalCellectis

Beyond the preview

Go deeper on Moligo Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moligo Technologies.

Explore the full profile